No Data
Bank of America Securities Keeps Their Buy Rating on Lyell Immunopharma (LYEL)
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‐stage T-cell reprogramming company advancing a diverse pipeline of cell therapies fo
Express News | HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $6 Price Target
Lyell Immunopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 136.22% HC Wainwright & Co. → $6 Reiterates Buy → Buy 02/29/2024 136.22% HC Wainwright & Co. $8
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows
Lyell Immunopharma (LYEL) shares were up nearly 4% in recent trading Monday, after Q1 net loss narrowed. The company reported Q1 net loss of $0.24 per diluted share, narrowing from a loss of $0.27 a y
Lyell Immunopharma | 10-Q: Quarterly report